How Long Does HRT Take to Work? The Timeline the Trials Actually Measured

How long does HRT take to work for hot flashes?

This exact question has some of the strongest evidence in menopause medicine. A Cochrane review pooled 24 double-blind randomized trials of oral HRT, 3,329 women in total, every trial at least three months long. HRT cut hot flash frequency by 17.9 flashes per week versus placebo, a 75% relative reduction (95% CI 64.3 to 82.3), and cut severity separately (odds ratio 0.13, 95% CI 0.07 to 0.23). Dropping out for lack of effect was about ten times more common on placebo.

The same review carries the number that should make you distrust week-one testimonials, your own included: women randomized to placebo saw a 57.7% reduction in hot flashes (95% CI 45.1 to 67.7) between baseline and end of study, and the reviewers note that symptoms may fluctuate on their own during menopause, which anyone in peri already knows. An early good week is real relief and weak evidence about your dose. The counts at week 4 and beyond are the signal.

The patch trials put a date on the onset. In two controlled trials of the Vivelle estradiol patch covering 356 women, the 0.075 and 0.1 mg doses were superior to placebo on vasomotor symptoms at weeks 4, 8 and 12, per the Minivelle label (Minivelle is bioequivalent to Vivelle). The trial that established the lowest dose enrolled women averaging 11.5 hot flashes per day at baseline, a useful reference for what "moderate to severe" means in these studies.

What should I expect in the first two weeks of starting HRT?

Prescribers start low on purpose, and the labels tell them to. The oral estradiol label sets the usual initial dose at 1 to 2 mg daily, "adjusted as necessary to control presenting symptoms." The patch label starts vasomotor treatment at 0.0375 mg per day, applied twice weekly, and says dosage adjustment "should be guided by the clinical response." Both sentences mean the same thing: your first prescription is an opening bid.

Here is what that opening bid did under trial conditions. In two of the three placebo-controlled studies on the patch label, the two lowest doses, 0.0375 and 0.05 mg, had not separated from placebo at week 4. A third study later established the 0.0375 mg dose at weeks 4 through 12. Translated: a woman on a standard starting dose can go a month with no detectable benefit while sitting one dose step below the amount that will work for her. That is the simplest honest explanation for "nothing is happening" in month one.

Meanwhile the side effects run on their own clock. The estradiol label's common side effects, all six of them: headache, breast pain, irregular vaginal bleeding or spotting, stomach or abdominal cramps and bloating, nausea and vomiting, and hair loss. If you have a uterus you will also be taking a progestogen with its own early effects; here is why the progesterone half is non-negotiable. And if you are on a patch, the dose only arrives if the patch stays stuck where the label says to put it: see our estrogen patch guide and where to place an estradiol patch.

What are the signs HRT is working?

Count. That is the entire method. The pivotal hot flash trials measured the thing you can measure for free: how many hot flashes and night sweats per day, and how severe. Write down your daily count for a week as you start, then keep the tally going. The trials scored frequency and severity separately, and both moved.

• Your daily flash count drops against your own baseline. Trial participants started around 11.5 per day in the lowest-dose patch study. Frequency is the number the pooled trials led with and the first thing worth writing down.
• The flashes you still get are weaker. Severity fell separately from frequency in the pooled trials (odds ratio 0.13 versus placebo), so "fewer" and "milder" are two different signs and you can have either one first.
• Night sweats stop waking you. Fewer sweats means fewer wake-ups. The estradiol label carries no separate indication for sleep or energy, so this indirect route is the one HRT actually has.
• By week 12, vaginal dryness and pain scores move, provided you are treating those symptoms with the right product (next section).

Also learn to tell a side effect from a failure. Breast pain and spotting in month one are listed label effects and a dose conversation for your prescriber, and they say nothing about whether the estrogen is failing. Our HRT side effects guide separates the common effects from the warning signs.

Why do vaginal symptoms take months instead of weeks?

Vaginal dryness, irritation, painful sex and the urinary symptoms that travel with them respond to estrogen on a tissue timescale. The trial behind Vagifem, the 10 mcg vaginal estradiol insert, dosed daily for two weeks and then twice weekly, and measured all of its co-primary endpoints at week 12. At that point the insert beat placebo on a composite score of the most bothersome symptoms, a drop of 1.20 points versus 0.84 on placebo.

Two practical consequences. First, give any vaginal estrogen product its full 12 weeks before you judge it. Second, these symptoms have their own product class: the oral estradiol label itself says that when prescribing solely for vulvar and vaginal atrophy, topical vaginal products should be considered. The Menopause Society's 2022 hormone therapy position statement calls hormone therapy the most effective treatment for both vasomotor symptoms and genitourinary syndrome of menopause, and recommends low-dose vaginal estrogen for bothersome genitourinary symptoms that over-the-counter options have not relieved, in women who have no separate reason for systemic therapy. Our vaginal estrogen hub covers the products and what they cost.

Which symptoms may never respond to HRT?

The estradiol tablet label lists its indications, and weight appears nowhere among them. Neither does hair. Where both do appear is the Adverse Reactions section: "Increase or decrease in weight" under Miscellaneous, naming both directions and attaching a rate to neither, and "Loss of scalp hair" under Skin.

So a response timeline for weight or hair on HRT does not exist, because the drug carries no claim to treat either one. If either is the main reason you started, the 3-month review will read as failure, and the real problem is that the prescription was aimed at a target the drug never claimed. We make this argument symptom by symptom on what HRT actually treats, and the randomized weight evidence, every confidence interval printed, lives at HRT and weight loss.

What happens at the 3-month review?

The review is written into the label. The oral estradiol label says patients "should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary," and separately that attempts to taper or discontinue should be made on the same 3-month to 6-month schedule. The Menopause Society's 2022 position statement says it in guideline language: individualize treatment and periodically re-evaluate the benefits and risks of continuing.

In practice the review has four outcomes: keep the dose, raise it, change the route or product, or add low-dose vaginal estrogen for genitourinary symptoms. Bring numbers. Your flash counts from weeks 0, 4 and 12 turn the appointment from "how do you feel" into a dose decision.

And if your provider never scheduled a 3-month review at all, that tells you something about the clinical model you are paying for. Follow-up depth is part of the clinical-depth dimension we score across every HRT provider we rank, and what ongoing care actually costs per provider is on our cost of HRT breakdown.

What does it mean if HRT is not working?

"Not working" has four honest meanings, and each has a different fix.

1. 1.Too early. Before week 4 there is no trial-measured efficacy signal on any of the systemic products covered above. Keep counting and hold until the first checkpoint, unless a warning sign appears.
2. 2.Dose too low. The first explanation to check at weeks 4 to 8 if your counts have not moved. The labels instruct adjustment by clinical response, and the trial record shows standard starting doses failing to separate from placebo at week 4. This is a phone call, and the fix can be one dose step.
3. 3.Wrong target symptom. If the complaint that sent you to HRT is weight, hair or brain fog, the label never promised movement there. Re-read what HRT treats and bring the actual symptom, named, to the review.
4. 4.Wrong route for the symptom. Hot flashes controlled while vaginal dryness or painful sex persists is a route question for the review, and vaginal estrogen runs on its own 12-week clock. The 2022 position statement recommends low-dose vaginal estrogen for bothersome genitourinary symptoms that over-the-counter options have not relieved.

Go back sooner than 3 months for any of the label's warning signs: breast lumps, unusual vaginal bleeding, dizziness or faintness, changes in speech, severe headache, chest pain, shortness of breath, pain in your legs, changes in vision, or vomiting. The label says to call your healthcare provider right away if you get any of these, and it requires a diagnostic workup to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. That rule outranks every timeline in this article.

If the problem is the provider, a platform that started you on a dose, never booked follow-up and takes a week to answer messages, switching is the fix available to you today. Our rankings weigh clinical depth and follow-up structure with no pay-for-placement, the two-minute match quiz shortlists by your situation, and the safety question that tends to resurface at this point is answered with primary sources at is HRT safe.